226256-56-0 Usage
Description
Cinacalcet, also known as Sensipar, is the first type II calcimimetic agent approved by the United States Food and Drug Administration. It functions by enhancing the sensitivity of the calcium-sensing receptor (CaSR) to calcium, leading to a decrease in parathyroid hormone (PTH) levels, as well as serum calcium and phosphorous levels. This secondary amino compound is characterized by its yellow oil appearance and is used for various therapeutic applications.
Uses
Used in Chronic Kidney Disease Treatment:
Cinacalcet is used as a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. By increasing the sensitivity of CaSR to calcium, it helps regulate PTH secretion, which in turn helps manage the complications associated with chronic kidney disease.
Used in Macular Degeneration Therapy:
Cinacalcet is also utilized in the treatment of macular degeneration, a condition that affects the central vision and can lead to vision loss. The exact mechanism of its application in this context is not provided in the materials, but it suggests a broader range of therapeutic uses for the compound.
Used in Mass Spectrometry:
Labeled Cinacalcet is employed as an internal standard for the quantification of Cinacalcet by gas chromatography (GC) or liquid chromatography (LC) mass spectrometry. This application is crucial in ensuring accurate and reliable measurements of Cinacalcet concentrations in various samples, which can be essential for research and quality control purposes in the pharmaceutical industry.
Mechanism
Cinacalcet is a basic single-chain peptide hormone secreted by the parathyroid chief cells , called PTH, it is a blend of 84 amino acids,it has an effect of elevating serum calcium and lowing phosphorus, regulating calcium and phosphorus metabolism balance of vertebrate body . In parathyroid cells,the first main precursor of PTH is synthesized at first, it is called Prepro-parathyroid, containing 115 amino acids, the predecessor of the substance after cell lysis in the thyroid becomes the second precursor substance,it is called parathyroid-hormone containing 90 amino acids , the latter becomes polypeptide containing 84 amino acids by cleaving within the cell, that is PTH. Normal human plasma PTH concentration is about 1 ng/ml.
The main physiological function of parathyroid hormone is promoting osteolysis, bone calcium mobilization into the blood, increasing calcium, increasing vigor of serum and bone alkaline phosphatase ;it can inhibit renal tubular reabsorption of phosphate, promote urinary excretion of phosphorus , decrease phosphorus; PTH via activation of vitamin D3, indirectly promotes intestinal absorption of calcium, magnesium and phosphorus. PTH secretion is mainly affected by the regulation of calcium concentration. Blood Ca2 + elevates, PTH secretion reduces; blood Ca2 + decreases, secretion is increased. In addition, phosphorus increasing via reducing calcium stimulates the secretion of PTH, calcitonin massive release can also promote increasing secretion of PTH.
Serum parathyroid hormone except for the study of parathyroid disease, has a certain value on the differential diagnosis of hypercalcemia and hypocalcemia The main clinical significance is as follows:
1. Diagnosis of parathyroid disease. When there are hyperparathyroidism or ectopic PTH secretion disorder, PTH increases ; when there are hypoparathyroidism, parathyroid surgery or radiation damage, etc., PTH decreases.
2. Identification of hypercalcemia and hypocalcemia. When abnormal calcium is caused by calcium parathyroid disorders ,serum calcium lifts as serum PTH lifts, while abnormal blood calcium is caused by other causes , PTH does not change.
The above information is edited by the lookchem of Tian Ye.
Clinical Use
Cinacalcet hydrochloride is a second-generat ion calcimimetic approved for the treatment of secondary
hyperparathyroidism in patients wi th chronic kidney disease on dialysis and for the treatment of hypercalcemia
in patients with parathyroid cancer . It can be used alone, with vitamin D, and/or with a phosphate binder .
Drug interactions
Potentially hazardous interactions with other drugs
Antifungals: metabolism inhibited by ketoconazole.
Hormone antagonists: metabolism of tamoxifen to
active metabolite inhibited - avoid.
Tobacco: metabolism increased by tobacco.
Metabolism
Cinacalcet is rapidly and extensively metabolised by
cytochrome P450 isoenzymes CYP3A4 and CYP1A2, by
oxidation followed by conjugation. The major circulating
metabolites are inactive, and are renally excreted, with
80% of the dose recovered in the urine, and 15% in the
faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 226256-56-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,6,2,5 and 6 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 226256-56:
(8*2)+(7*2)+(6*6)+(5*2)+(4*5)+(3*6)+(2*5)+(1*6)=130
130 % 10 = 0
So 226256-56-0 is a valid CAS Registry Number.
InChI:InChI=1/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
226256-56-0Relevant articles and documents
Efficient synthesis of cinacalcet hydrochloride
Bijukumar, Gopinathenpillai,Maloyesh, Biswas,Bhaskar, Bhirud Shekhar,Rajendra, Agarwal
, p. 1512 - 1517 (2008)
A new route to synthesize cinacalcet hydrochloride ((R)-α-methyl-N- [3-[3-(trifluoromethyl) phenyl] propyl]-1-naphthalene methane amine hydrochloride) has been described. The key steps include the Knoevenagel-Doebner condensation and the amide reduction under milder conditions. Copyright Taylor & Francis Group, LLC.
Preparation method of cinacalcet hydrochloride
-
, (2021/05/26)
The invention discloses a method for preparing cinacalcet hydrochloride. The method comprises the following steps: performing condensation reaction on m-trifluoromethyl benzaldehyde serving as a starting raw material and acetaldehyde to prepare m-trifluoromethyl cinnamyl aldehyde, directly obtaining an oxalate intermediate from the m-trifluoromethyl cinnamyl aldehyde and R-1-(1-naphthyl) ethyl amine by a one-pot method to avoid impurity increase caused by separation of an unstable intermediate namely imine, desalting oxalate, carrying out Pd/C catalytic hydrogenation to obtain cinacalcet, and carrying out a reaction on cinacalcet and hydrochloric acid to finally obtain cinacalcet hydrochloride. The synthesis method disclosed by the invention is green, environment-friendly, economical and practical, simple to operate and more beneficial to industrial production.
BF3·Et2O as a metal-free catalyst for direct reductive amination of aldehydes with amines using formic acid as a reductant
Fan, Qing-Hua,Liu, Xintong,Luo, Zhenli,Pan, Yixiao,Xu, Lijin,Yang, Ji,Yao, Zhen,Zhang, Xin
supporting information, p. 5205 - 5211 (2021/07/29)
A versatile metal- and base-free direct reductive amination of aldehydes with amines using formic acid as a reductant under the catalysis of inexpensive BF3·Et2O has been developed. A wide range of primary and secondary amines and diversely substituted aldehydes are compatible with this transformation, allowing facile access to various secondary and tertiary amines in high yields with wide functional group tolerance. Moreover, the method is convenient for the late-stage functionalization of bioactive compounds and preparation of commercialized drug molecules and biologically relevant N-heterocycles. The procedure has the advantages of simple operation and workup and easy scale-up, and does not require dry conditions, an inert atmosphere or a water scavenger. Mechanistic studies reveal the involvement of imine activation by BF3and hydride transfer from formic acid.